Industry leaves poverty-related research:
This article was originally published in Clinica
Industry has been discouraged from investing in research to tackle poverty-related diseases, such as malaria, tuberculosis and AIDS, because of the lack of returns. It is now up to the European Community to fill this gap by giving its financial support, EU Research Commissioner Philippe Busquin has said. Speaking at the launch of the European Commission's programme of clinical trials for poverty-related diseases he said that the programme will improve the impact of public investment by allowing a more coherent and targeted approach. He added that the clinical trials programme will help create a critical mass of research competence and establish a more structured partnership. The European Community is allocating E200 million ($182 million) to the programme over five years under the Sixth Framework Programme for research.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.